• Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D

    9 days ago - By Xconomy

    Emendo Biotherapeutics, a company aiming to apply CRISPR gene editing to a wider range of genetic diseases, has raised $61 million in financing. The Series B round was led by AnGes, a Japan-based biopharmaceutical company. New York-based Emendo did not respond to a request for comment. But on its website, it contends that CRISPR is limited in its ability to treat dominant genetic diseases, which are diseases caused by a mutation to one copy of a gene. Treating these diseases, which represent the majority of genetic disorders, require edits to the mutated gene while leaving the other one...
    Read more ...